A partir de cette page vous pouvez :
Retourner au premier écran avec les dernières notices... |
Détail de l'auteur
Auteur Thomas Chester
Documents disponibles écrits par cet auteur
Ajouter le résultat dans votre panier Affiner la rechercheLocalized Heat Treatment for Meibomian Gland Dysfunction: A Single-Center Retrospective Analysis of Efficacy over Time / Thomas Chester in OVS : Optometry & Vision Science, vol. 100, 09 (Septembre 2023)
[article]
in OVS : Optometry & Vision Science > vol. 100, 09 (Septembre 2023)
Titre : Localized Heat Treatment for Meibomian Gland Dysfunction: A Single-Center Retrospective Analysis of Efficacy over Time Type de document : article de périodique Auteurs : Thomas Chester ; Tanner Ferguson ; Emma Chester Année de publication : 2023 Langues : Français (fre) Descripteurs (mots clés) : [Thésaurus Mesh]Collecte de données
[Thésaurus Mesh]dysfonctionnement des glandes de Meibomius
[Thésaurus Mesh]Ophtalmologie
[Thésaurus Mesh]Optométrie
[Thésaurus Mesh]Résultat thérapeutique
[Thésaurus Mesh]Signes et symptômes
[Thésaurus Mesh]ThérapeutiqueMots-clés : Traitement thermique localisé Résumé : SIGNIFICANCE
Meibomian gland dysfunction (MGD) can produce a myriad of symptoms. The effective treatment of MGD can reduce the burden of this condition. Although several studies have indicated that TearCare (Sight Sciences, Menlo Park, CA) is an effective treatment for MGD, no studies currently provide information regarding the duration of efficacy.
PURPOSE
The purpose of this analysis was to determine the duration of efficacy of symptom relief and improvement of signs (as measured by gland function) for a treatment consisting of controlled heating of the meibomian glands using SmartLids (Sight Sciences) combined with manual expression of the liquefied meibum by a physician.
METHODS
This study involved retrospective analysis of data gathered from a single-center ophthalmology/optometry practice. Symptoms were assessed using the Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire, and the signs were assessed using the meibomian gland expression (MGE) scores before and at several time points (8 weeks, 6 months, 12 months, and 18 months). Further analysis evaluating the efficacy in subgroups based on age, race, and sex was performed.
RESULTS
There were 78 patients included in this study. The mean baseline SPEED score decreased from 14 to 7.9 at 8 weeks. The mean SPEED scores at 6 and 12 months were maintained at 7.7 and 7.9, respectively, and at 18 months went to 8.9. At baseline, the mean MGE was 4.9 in the right eye and 4.8 in the left eye. In both eyes, the mean MGE increased to 9.0 in both eyes at 8 weeks. At 6 months, the mean MGE score was maintained at 8.6 in the right and 8.2 in the left and remained consistent at 12 months with 7.8 in the right and 7.8 in the left. At 18 months, the MGE score went to 6.8 in the right eye and 7.0 in the left eye.
CONCLUSIONS
A single TearCare treatment effectively reduced both the symptoms and signs of MGD and maintained its effects for 12 months.Permalink : https://bibliotheque.helb-prigogine.be/opac_css/index.php?lvl=notice_display&id= [article]Exemplaires
Cote Support Localisation Section Disponibilité aucun exemplaire A Single-center Retrospective Trial of a Blink-assisted Eyelid Device in Treating the Signs and Symptoms of Dry Eye / Thomas Chester in OVS : Optometry & Vision Science, vol. 98, 06 (Juin 2012)
[article]
in OVS : Optometry & Vision Science > vol. 98, 06 (Juin 2012)
Titre : A Single-center Retrospective Trial of a Blink-assisted Eyelid Device in Treating the Signs and Symptoms of Dry Eye Type de document : article de périodique Auteurs : Thomas Chester Année de publication : 2021 Langues : Français (fre) Descripteurs (mots clés) : [Thésaurus Mesh]Signes et symptômes
[Thésaurus Mesh]Syndromes de l'oeil sec
[Thésaurus Mesh]Thérapeutique
[Thésaurus HELB]:Paramédical:Glandes de MeibomiusRésumé : SIGNIFICANCE: The clinical features of meibomian gland disease include altered tear film stability, damage to the ocular surface, symptoms of ocular surface irritation, and visual fluctuations. Finding an adequate treatment to alleviate a patient's signs and symptoms is vital to caring for those with dry eye disease resulting from meibomian gland disease. PURPOSE: The purpose of this analysis was to determine whether the controlled heating of meibomian glands with the SmartLid devices (TearCare) combined with evacuation of the liquefied meibum using a handheld clearance assistant would improve a patient's dry eye symptoms (as measured by the Standardized Patient Evaluation of Eye Dryness [SPEED] questionnaire) and signs (as measured by meibomian gland expression [MGE] scores). METHODS: This study involved a retrospective analysis of data gathered in a single-center ophthalmology/ optometry practice. The symptom frequency and severity were assessed using the SPEED questionnaire, and the signs were assessed via MGE scores before and after (8 to 12 weeks) treatment. A further analysis evaluating efficacy in subgroups based on age, race, and sex was performed. A statistical analysis was performed with t tests for group comparisons. RESULTS: A SPEED questionnaire was answered by 92 patients with dry eye disease. In addition, each patient's meibomian gland function was recorded as MGE scores for each eye (176 eyes). These procedures were completed before and approximately 8 weeks after a single bilateral TearCare treatment. The median total SPEED score was reduced from 16 to 9, and the total MGE scores improved from 5.0 to 9.0 in the right eye and 4.0 to 9.0 in the left eye after a single TearCare treatment. CONCLUSIONS: A single TearCare treatment was effective in reducing both the signs and symptoms of dry eye in all subjects Permalink : https://bibliotheque.helb-prigogine.be/opac_css/index.php?lvl=notice_display&id= [article]Exemplaires
Cote Support Localisation Section Disponibilité aucun exemplaire